Drugs Containing Excipient (Inactive Ingredient) PARAFFINUM LIQUIDUM

« Back to Dashboard

Generic drugs containing PARAFFINUM LIQUIDUM excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	triamcinolone acetonide	50090-0228	PARAFFINUM LIQUIDUM
A-S Medication Solutions	triamcinolone acetonide	50090-2106	PARAFFINUM LIQUIDUM
A-S Medication Solutions	bacitracin zinc and polymyxin b sulfate	50090-7189	PARAFFINUM LIQUIDUM

Paraffinum Liquidum Market Dynamics and Financial Trajectory

Last updated: August 14, 2026

Paraffinum liquidum, also called liquid paraffin, mineral oil, or white mineral oil, is a mature petroleum-derived excipient used in oral laxatives, topical products, ointments, creams, capsules, and pharmaceutical processing. Its financial outlook is stable rather than high-growth. Volume demand is tied to established dosage forms, while revenue depends on pharmaceutical-grade purity, regulatory documentation, refining costs, energy prices, and supply reliability.

The market has limited standalone disclosure. Producers generally report pharmaceutical white oils within broader specialty chemicals, petroleum products, personal-care ingredients, or industrial mineral-oil portfolios. Public filings therefore do not support a precise global market size or a standalone revenue forecast. The most defensible investment view is a low-single-digit volume market with periodic price volatility and modest premium growth for certified, high-purity grades.

What is paraffinum liquidum and how is it used in pharmaceuticals?

Paraffinum liquidum is a highly refined mixture of liquid saturated hydrocarbons derived primarily from petroleum. Pharmaceutical grades are processed to remove sulfur compounds, aromatics, polycyclic aromatic hydrocarbons, color bodies, and other impurities.

Typical pharmaceutical applications include:

Application	Function of paraffinum liquidum	Commercial characteristics
Oral laxatives	Lubricant and stool-softening agent	High-volume, mature demand
Ointments and creams	Emollient, occlusive, and viscosity modifier	Competes with petrolatum, esters, and silicone oils
Soft and hard capsules	Lubricant or processing aid in selected formulations	Requires compatibility and quality documentation
Topical pharmaceutical bases	Vehicle and spreading agent	Sensitive to cosmetic and dermatology trends
Manufacturing processes	Lubricant, release aid, or processing component	Often purchased under technical or pharmaceutical specifications
Veterinary medicines	Carrier or topical vehicle	Smaller but diversified demand base

The principal pharmacopeial identity is controlled through specifications covering appearance, viscosity, density, acidity or alkalinity, sulfur compounds, readily carbonizable substances, polycyclic aromatic hydrocarbons, and related purity attributes. The United States Pharmacopeia-National Formulary and European Pharmacopoeia are central quality references for pharmaceutical buyers.[1][2]

How large is the paraffinum liquidum pharmaceutical market?

No authoritative public source reports a globally audited market size for pharmaceutical paraffinum liquidum alone. Suppliers typically combine it with white oils, process oils, medical-grade mineral oils, or specialty hydrocarbons.

The addressable market is best understood through three layers:

1. Pharmaceutical-grade liquid paraffin used as an excipient.
2. Medical and personal-care white oils that may share refining infrastructure.
3. Industrial and food-grade mineral oils that use related feedstocks but have different regulatory specifications.

Pharmaceutical demand is smaller than industrial and cosmetic demand, but it carries higher documentation and qualification requirements. A pharmaceutical buyer may pay a premium for:

• USP-NF, Ph. Eur., JP, or multi-compendial compliance.
• Drug Master File or equivalent regulatory support.
• Lot-level traceability.
• Low aromatic and PAH content.
• Consistent viscosity and density.
• Change-control commitments.
• Auditable manufacturing and testing systems.
• Regional inventory and validated logistics.

The commercial value of pharmaceutical paraffinum liquidum is therefore determined more by quality tier and customer qualification than by the commodity price of mineral oil.

What drives paraffinum liquidum market growth?

Pharmaceutical volume demand

Demand from oral laxatives is relatively stable because mineral oil products are established over-the-counter medicines. Growth is limited by mature use patterns, safety labeling, physician preference, and substitution by polyethylene glycol, stimulant laxatives, stool softeners, and fiber products.

Topical pharmaceutical demand has stronger product-level variation. Dermatology, wound care, barrier products, and emollient formulations continue to use mineral hydrocarbons, but formulators also evaluate triglycerides, synthetic esters, dimethicone, hydrogenated polyisobutene, and plant-derived alternatives.

Dermatology and self-care

Paraffinum liquidum remains common in emollient and barrier products because it is chemically stable, inexpensive, low-odor, and well understood by regulators. The main commercial risk comes from brand positioning rather than technical performance. Some consumer brands avoid petroleum-derived ingredients for sustainability or marketing reasons, creating substitution pressure in cosmetics and selected topical products.

Pharmaceutical dermatology has lower substitution risk when the excipient is embedded in a validated formulation or linked to a long-established product specification.

Regional manufacturing growth

Demand is supported by generic-drug manufacturing, contract manufacturing, and pharmaceutical production in India, China, Southeast Asia, Latin America, and the Middle East. These regions add formulation capacity but also create price pressure because buyers often qualify multiple regional sources.

European and North American customers tend to place greater weight on documentation, inspection history, supply continuity, and change-control systems. Emerging-market customers may place greater weight on price, delivery time, and local regulatory registration.

How does the paraffinum liquidum supply chain work?

The supply chain begins with petroleum fractions that undergo distillation, solvent extraction, hydrogenation, hydrofinishing, dewaxing, and filtration. The precise process varies by producer and target viscosity grade.

Key cost inputs include:

• Crude-oil and feedstock prices.
• Refinery utilization.
• Hydrogen and natural-gas costs.
• Electricity and logistics.
• Capacity for deep purification.
• Packaging and regional warehousing.
• Quality-control testing.
• Regulatory maintenance.

Pharmaceutical-grade production is not simply a matter of purchasing industrial mineral oil and applying a certificate of analysis. A supplier must maintain process controls, validated testing, controlled change management, and a consistent impurity profile.

Qualification creates switching friction. A drug manufacturer may need to assess new grades for viscosity, spreadability, API compatibility, extractables and leachables, stability, microbial risk, process performance, and regulatory filing impact. This supports incumbent suppliers once a grade is approved.

Which companies supply pharmaceutical-grade paraffinum liquidum?

The supplier landscape is fragmented and includes specialty white-oil producers, petroleum refiners, and distributors. Companies associated with pharmaceutical, medical, cosmetic, or high-purity white-oil products include:

Supplier or supplier group	Relevant commercial position
Sonneborn	Specialty hydrocarbon and white-oil products, including pharmaceutical and personal-care grades
Calumet Specialty Products Partners	Specialty products and mineral-oil grades marketed under product families such as Drakeol
Sasol	High-purity hydrocarbon and specialty chemical capabilities
Petro-Canada Lubricants	Highly refined white oils and specialty hydrocarbon products
Nynas	Specialty naphthenic oils, with product overlap in certain industrial and formulation markets
Regional refiners and distributors	Local pharmaceutical-grade supply, repackaging, and regulatory support

Supplier positioning differs by region. Some companies own refining assets, while others rely on contracted production and focus on qualification, packaging, distribution, and regulatory service.

What is the financial trajectory for paraffinum liquidum?

The financial trajectory is likely to follow a stable-volume, price-sensitive pattern.

Financial variable	Expected direction	Principal driver
Pharmaceutical volume	Low growth to broadly stable	Mature laxative and topical use
Average selling price	Cyclical	Feedstock, energy, freight, and capacity
Pharmaceutical-grade premium	Stable to modestly positive	Compliance, documentation, and qualification
Gross margin	Variable	Refining costs and product mix
Capital intensity	Moderate to high	Purification, storage, testing, and environmental controls
Customer retention	Relatively strong after qualification	Regulatory and formulation switching costs
Substitution risk	Moderate in cosmetics; lower in validated medicines	Plant-derived and synthetic alternatives
Supplier concentration	Moderate	Limited number of qualified high-purity producers

The strongest financial exposure is at the supplier level rather than at the excipient level. A company with a broad specialty-products portfolio may benefit from pharmaceutical white oils but remain materially exposed to industrial, automotive, food, or personal-care markets. A rise in paraffinum liquidum prices may therefore reflect broader refinery economics rather than pharmaceutical demand.

Revenue growth can come from three sources:

1. Price increases passed through from crude, energy, and logistics.
2. Conversion of industrial or cosmetic customers to higher-value pharmaceutical grades.
3. Geographic expansion through local inventory and regulatory registrations.

Volume-led growth is more difficult because the core pharmaceutical applications are mature and the excipient is usually used at relatively low cost per finished dose.

What regulatory status applies to paraffinum liquidum?

Paraffinum liquidum is regulated through the finished drug, excipient specification, manufacturing controls, and intended use. The regulatory status differs by jurisdiction and dosage form.

In the United States, mineral oil is recognized in FDA over-the-counter laxative regulation, while inactive-ingredient acceptability is assessed through the FDA Inactive Ingredient Database and product-specific review.[3][4] A particular grade does not receive universal approval merely because the chemical name is accepted. The manufacturer must demonstrate that the grade is appropriate for the intended route, concentration, and dosage form.

In Europe, liquid paraffin is governed through the European Pharmacopoeia and national or centralized product requirements. Pharmaceutical companies generally require a supplier qualification package covering specification, impurities, manufacturing site, stability, change control, and audit history.[2]

Pharmaceutical buyers commonly request:

• Certificate of analysis.
• Compendial compliance statement.
• Residual solvent and elemental impurity information.
• PAH and aromatic hydrocarbon data.
• Allergen and animal-origin statements.
• TSE/BSE statements where applicable.
• Nitrosamine risk assessment when relevant to the formulation.
• GMP or quality-system documentation.
• Supply-chain and manufacturing-site information.

What patents protect paraffinum liquidum?

The base excipient is a longstanding petroleum-derived material and does not have a meaningful active-ingredient patent estate. Patent value is concentrated in manufacturing processes, purification methods, compositions, and finished pharmaceutical formulations.

Potentially relevant patent categories include:

• Hydroprocessing and hydrogenation methods.
• Removal of aromatic or polycyclic impurities.
• Narrow-viscosity white-oil compositions.
• Mineral-oil and petrolatum topical bases.
• Controlled-release or lubricant systems containing mineral oil.
• Oral laxative combinations.
• Dermatological formulations with specific ratios of mineral oil and other excipients.
• Capsule manufacturing and coating systems.

These rights are usually difficult to enforce against the broader excipient market because a formulation patent may cover a finished composition rather than the supplier’s generic liquid paraffin. Patent claims directed only to a known excipient face novelty and obviousness challenges unless they include a new impurity profile, performance property, process, or therapeutic formulation.

Does paraffinum liquidum have Orange Book or Paragraph IV risk?

Paraffinum liquidum itself does not have an Orange Book listing because it is an excipient, not an approved drug product. Orange Book and Paragraph IV issues arise at the finished-product level.

A generic company using liquid paraffin in an oral laxative or topical product may face:

• Method-of-use patents.
• Formulation patents.
• Device or packaging patents.
• Labeling restrictions.
• Product-specific exclusivity.
• Bioequivalence or therapeutic-equivalence requirements.

A Paragraph IV certification would challenge a patent listed for the reference drug product, not a patent on the excipient as such. The commercial risk depends on the finished product’s patent and exclusivity profile.

What manufacturing and intellectual-property barriers exist?

The primary barrier is qualification rather than patent exclusion. A new supplier may need to reproduce the incumbent grade’s technical performance and regulatory history across multiple customers.

Important barriers include:

• Consistent feedstock selection.
• Deep removal of aromatic impurities.
• Stable viscosity across lots.
• Long-term supply contracts.
• Validated packaging systems.
• Customer audits.
• Regional pharmacopoeial compliance.
• Environmental permits for refining and hydrogenation.
• Testing capability for hydrocarbons and trace impurities.

These barriers favor established suppliers but do not create the same exclusivity economics associated with patented APIs or biologics. A technically capable refiner can enter if it has appropriate purification assets and can complete customer qualification.

How does paraffinum liquidum compare with competing excipients?

Attribute	Paraffinum liquidum	Petrolatum	Dimethicone	Plant-derived oils
Chemical stability	High	High	Very high	Variable
Occlusive effect	High	Very high	Moderate to high	Variable
Cost	Low to moderate	Low to moderate	Moderate to high	Variable
Petroleum-derived	Yes	Yes	No, silicone-based	No
Oxidation risk	Low	Low	Very low	Often higher
Formulation familiarity	Extensive	Extensive	Extensive	Increasing
Sustainability pressure	High	High	Moderate	Lower in some markets
Pharmaceutical qualification base	Strong	Strong	Strong	Product-dependent

Paraffinum liquidum remains competitive where low cost, stability, and established regulatory use outweigh sustainability preferences. Dimethicone is stronger in selected sensory and barrier applications. Plant-derived oils have marketing advantages but can introduce oxidation, odor, allergen, and batch-variability concerns.

What generic entry and commercial risks exist?

Generic-entry risk for products containing paraffinum liquidum is usually moderate. The excipient is widely available, and no material ingredient-level exclusivity blocks substitution. The main constraints are finished-product approval, formulation reproducibility, and supplier qualification.

Commercial risks include:

• Crude and energy volatility.
• Refinery outages.
• Restrictions on petroleum-derived ingredients.
• Customer migration to synthetic or plant-derived alternatives.
• Loss of a major finished-drug customer.
• Tightening impurity standards.
• Transport and storage disruption.
• Supplier consolidation.
• Product-specific patent litigation involving the finished medicine.

For investors, the excipient should be assessed as part of a supplier’s specialty-refining portfolio. Standalone pharmaceutical demand is unlikely to generate the growth profile of a novel API, biologic, or advanced delivery technology.

Key Takeaways

• Paraffinum liquidum is a mature, widely used pharmaceutical excipient with stable core demand.
• Pharmaceutical-grade value comes from purity, documentation, qualification, and reliable supply rather than ingredient exclusivity.
• Public companies generally do not disclose separate paraffinum liquidum revenue, preventing a reliable standalone global market-size estimate.
• Revenue is more sensitive to feedstock, energy, refining capacity, and product mix than to pharmaceutical volume growth.
• Oral laxatives and topical dermatology products are the principal pharmaceutical demand pools.
• Cosmetic substitution by plant-derived oils and synthetic emollients is a greater risk than substitution in validated pharmaceutical formulations.
• The excipient itself has no meaningful Orange Book or Paragraph IV exposure.
• Patent risk is concentrated in finished formulations, purification processes, and method-of-use claims.
• Supplier qualification and impurity-control capability are the main barriers to entry.
• The likely financial profile is stable volume, cyclical pricing, and modest premium growth for high-purity, multi-compendial grades.

FAQs

Is paraffinum liquidum the same as mineral oil?

Yes. In pharmaceutical and cosmetic commerce, paraffinum liquidum generally refers to highly refined liquid paraffin or white mineral oil. The applicable grade and specification determine whether it is suitable for pharmaceutical use.

Is paraffinum liquidum safe in oral medicines?

Safety depends on route, dose, product labeling, patient population, and regulatory compliance. Mineral oil is recognized for certain over-the-counter laxative uses in the United States, but the finished product must meet applicable FDA requirements.[3]

Can pharmaceutical manufacturers switch liquid paraffin suppliers easily?

Usually not. The material is commercially available, but a supplier change may require technical evaluation, stability work, quality audits, and regulatory assessment. Switching is easier when the new material is multi-compendial and closely matches the approved grade.

Are there biosimilars for paraffinum liquidum?

No. Paraffinum liquidum is a small-molecule petroleum-derived excipient, not a biologic. Biosimilar pathways do not apply.

Does petroleum origin prevent pharmaceutical use of paraffinum liquidum?

No. Pharmaceutical use depends on refining, impurity control, compendial compliance, manufacturing quality, and the intended formulation. Petroleum origin can affect consumer positioning and substitution decisions, but it does not by itself prevent pharmaceutical use.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Mineral oil monograph. USP-NF.

2. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Liquid paraffin monograph. Council of Europe.

3. U.S. Food and Drug Administration. (2024). Laxative drug products for over-the-counter human use. Code of Federal Regulations, Title 21, Part 334.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase